KPRX
Income statement / Annual
Last year (2023), Kiora Pharmaceuticals, Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2023, Kiora Pharmaceuticals, Inc.'s net income was -$12.51 M.
See Kiora Pharmaceuticals, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$12,059.00 |
$2.69 M |
$1.65 M |
$407,518.00 |
$669,259.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$4.03 M
|
$134,028.00
|
$227,273.00
|
$200,221.00
|
$4,889.36
|
$8.06 M
|
$10.33 M
|
$8.42 M
|
$1,257.00
|
$0.00
|
| Gross Profit |
-$4.03 M
|
-$134,028.00
|
-$227,273.00
|
-$188,162.00
|
$2.68 M
|
-$6.40 M
|
-$9.92 M
|
-$7.75 M
|
-$1,257.00
|
$0.00
|
| Gross Profit Ratio |
0
|
0
|
0
|
-15.6
|
1
|
-3.87
|
-24.35
|
-11.58
|
0
|
0
|
| Research and Development Expenses |
$4.03 M
|
$3.45 M
|
$5.35 M
|
$3.57 M
|
$5.39 M
|
$8.06 M
|
$10.33 M
|
$8.42 M
|
$2.72 M
|
$531,116.00
|
| General & Administrative Expenses |
$4.66 M
|
$8.28 M
|
$5.32 M
|
$4.66 M
|
$4.41 M
|
$4.44 M
|
$4.64 M
|
$5.59 M
|
$3.96 M
|
$1.93 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$4.66 M
|
$8.28 M
|
$5.32 M
|
$4.66 M
|
$4.41 M
|
$4.44 M
|
$4.64 M
|
$5.59 M
|
$3.96 M
|
$1.93 M
|
| Other Expenses |
-$130,324.00
|
$582,605.00
|
$6.27 M
|
$0.00
|
$0.00
|
$0.00
|
$4.64 M
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$8.56 M
|
$11.73 M
|
$10.67 M
|
$8.22 M
|
$9.80 M
|
$12.50 M
|
$14.97 M
|
$14.02 M
|
$6.68 M
|
$2.46 M
|
| Cost And Expenses |
$12.59 M
|
$11.73 M
|
$10.67 M
|
$8.22 M
|
$9.80 M
|
$12.50 M
|
$14.97 M
|
$14.02 M
|
$6.68 M
|
$2.46 M
|
| Interest Income |
$173,989.00
|
$56,891.00
|
$1,141.00
|
$23,339.00
|
$108,066.00
|
$120,363.00
|
$564.00
|
$3,684.00
|
$947.00
|
$1,102.00
|
| Interest Expense |
$11,132.00
|
$8,599.00
|
$6,851.00
|
$4,186.00
|
$325.00
|
$1,040.00
|
$1,215.00
|
$275.00
|
$1.93 M
|
$441,720.00
|
| Depreciation & Amortization |
$62,424.00
|
$134,028.00
|
$227,273.00
|
$200,221.00
|
$213,933.00
|
$38,483.00
|
$19,288.00
|
$5,185.00
|
$1,257.00
|
$1,724.00
|
| EBITDA |
-$12.35 M |
-$13.55 M |
-$13.73 M |
-$6.65 M |
-$6.79 M |
-$10.69 M |
-$14.54 M |
-$13.34 M |
-$6.68 M |
-$2.24 M |
| EBITDA Ratio |
0
|
0
|
0
|
-676.34
|
-2.53
|
-6.47
|
-35.68
|
-19.93
|
0
|
0
|
| Operating Income Ratio |
0
|
0
|
0
|
-679.11
|
-2.61
|
-6.56
|
-35.73
|
-19.94
|
0
|
0
|
| Total Other Income/Expenses Net |
$163,319.00
|
-$1.39 M
|
$272,480.00
|
$19,153.00
|
$107,741.00
|
$119,323.00
|
-$91,705.00
|
$3,409.00
|
$1.01 M
|
$709,817.00
|
| Income Before Tax |
-$12.42 M
|
-$13.70 M
|
-$16.70 M
|
-$8.08 M
|
-$7.00 M
|
-$10.73 M
|
-$14.56 M
|
-$13.34 M
|
-$8.39 M
|
-$1.55 M
|
| Income Before Tax Ratio |
0
|
0
|
0
|
-670.03
|
-2.61
|
-6.49
|
-35.73
|
-19.94
|
0
|
0
|
| Income Tax Expense |
$90,319.00
|
-$113,010.00
|
-$304,781.00
|
$12,055.00
|
$95,396.00
|
$86,045.00
|
-$1.34 M
|
$3,684.00
|
$1.94 M
|
$664,204.00
|
| Net Income |
-$12.51 M
|
-$13.58 M
|
-$16.39 M
|
-$8.09 M
|
-$7.10 M
|
-$10.81 M
|
-$13.22 M
|
-$13.34 M
|
-$8.39 M
|
-$1.77 M
|
| Net Income Ratio |
0
|
0
|
0
|
-671.03
|
-2.64
|
-6.54
|
-32.44
|
-19.94
|
0
|
0
|
| EPS |
-24.25 |
-18.55 |
-68 |
-70.5 |
-89.24 |
-182.81 |
-556.17 |
-906.3 |
-817.01 |
-153.35 |
| EPS Diluted |
-24.25 |
-18.55 |
-68 |
-70.5 |
-89.24 |
-182.81 |
-556.17 |
-906.3 |
-817.01 |
-153.35 |
| Weighted Average Shares Out |
$538,007.00
|
$732,303.00
|
$241,099.00
|
$114,787.00
|
$79,525.00
|
$59,139.00
|
$23,766.00
|
$14,723.00
|
$10,273.00
|
$11,568.00
|
| Weighted Average Shares Out Diluted |
$538,007.00
|
$732,303.00
|
$241,099.00
|
$114,787.00
|
$79,525.00
|
$59,139.00
|
$23,766.00
|
$14,723.00
|
$10,273.00
|
$11,568.00
|
| Link |
|
|
|
|
|
|
|
|
|
|
